What Steri-Pharma does

Steri-Pharma is a privately held pharmaceutical manufacturer specializing in sterile human antibiotics, headquartered at 429 So. West Street, Syracuse, NY. The company operates a single GMP-compliant manufacturing facility of more than 70,000 square feet, including a 19,000 square foot expansion adding sterile production rooms, filling rooms, and warehouse capacity. Operations encompass regulated research, manufacturing, testing, and distribution under a global quality management system, with distribution approvals in 40 countries across North America, Europe, Latin America, and Asia.

The company's product portfolio is concentrated in one category — human sterile antibiotics — supplied to global pharmaceutical distributors via B2B wholesale channels. Pricing, contract structures, and distributor identities are not publicly disclosed. Steri-Pharma positions itself on regulatory compliance, product quality, and reliable delivery supported by climate-controlled storage and advanced transport logistics.

Steri-Pharma is independently owned with no disclosed parent company, investors, or board composition. The company maintains an active website and recruits across quality, production, maintenance, accounting, HR, and engineering functions via ADP. No revenue, headcount trend, funding history, or leadership information is publicly available, and the source material contains no record of patents, partnerships, awards, or AI/ML capabilities.

Name

Steri-Pharma

Legal name

Steri-Pharma

Website

https://steri-pharma.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Steri-Pharma is a privately held, GMP-compliant pharmaceutical manufacturer of sterile human antibiotics, operating from a 70,000+ sq ft facility in Syracuse, NY, and distributing to pharmaceutical wholesalers across 40 countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Syracuse

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Infrastructure, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Steri-Pharma generates revenue through the manufacture and sale of sterile human antibiotics to global pharmaceutical markets and distributors across 40 approved countries.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Steri-Pharma manufactures and distributes sterile human antibiotics from a centralized GMP-compliant facility in Syracuse, New York. The company operates a manufacturing footprint of more than 70,000 square feet (with a 19,000 square foot expansion for sterile production, filling rooms, and warehouse space) and supplies its antibiotic products to pharmaceutical distributors across 40 approved countries in North America, Europe, Latin America, and Asia.

Product overview

Steri-Pharma is a single-product pharmaceutical company specializing in the manufacturing and global distribution of human sterile antibiotics. The company operates from one centralized manufacturing facility in Syracuse, NY with a footprint of over 70,000 square feet plus a 19,000 square foot expansion. Their product portfolio consists of human anti-biotics distributed to 40 approved countries across North America, Europe, Latin America, and Asia.

Differentiator

Problem solved

Functional benefit

Products and services

• Human Sterile Antibiotics

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves2 records

Expansion highlights3 records

Direct peers

• Hikma Pharmaceuticals: Global generic injectable pharmaceutical manufacturer with a large sterile injectables portfolio including antibiotics; most directly comparable to Steri-Pharma in product category, B2B distributor model, and international regulatory footprint.
• Amphastar Pharmaceuticals: US-based specialty pharmaceutical company focused on injectable and intranasal products including sterile antibiotics; comparable in scale, single-product/specialty focus, and regulatory-driven competitive positioning.
• Xellia Pharmaceuticals: Specialty manufacturer of anti-infective sterile injectable pharmaceuticals with global distribution; directly comparable product portfolio (sterile antibiotics) and B2B distribution model.
• Sagent Pharmaceuticals: US-based specialty injectable pharmaceutical company with a portfolio of generic injectable products including antibiotics; comparable in product category, customer base (hospital/distributor), and regulatory-driven operating model.

Broad incumbents

• Hospira (Pfizer Injectables): Largest US sterile injectable manufacturer prior to Pfizer acquisition; overlaps directly with Steri-Pharma's product category and B2B distribution model but operates as part of Pfizer's broader portfolio at much greater scale.
• Fresenius Kabi: Global pharmaceutical company specializing in injectable generic drugs and infusion solutions including sterile antibiotics; comparable product category and global distribution, but operates as part of the larger Fresenius Group.
• Dr. Reddy's Laboratories: Global generic pharmaceutical manufacturer with a significant sterile injectable portfolio including antibiotics; comparable in product category and global distribution across regulated markets.
• Aurobindo Pharma: Indian-headquartered global generic pharmaceutical company with a large injectable antibiotics portfolio; comparable product category and global B2B distribution, though at substantially larger scale.
• Sandoz (Novartis): Global leader in generic pharmaceuticals including a substantial sterile injectable antibiotics business; comparable product category and international regulatory footprint, operating at significantly larger scale.
• Lupin Pharmaceuticals: Global generic pharmaceutical manufacturer with sterile injectable products including antibiotics; comparable in B2B distribution model and regulated international markets, though operating at much larger scale across multiple therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Steri-Pharma